Donna Lombardi was diagnosed five years ago and reached out after chief meteorologist Roger Griswold shared his diagnosis.

Patients taking ACE inhibitors and ARBs saw a 16% reduction in their risk of cancer progression (HR, 0.84; 95% CI, 0.71-0.99; ...

On Thursday, the U.S. Food and Drug Administration approved Johnson & Johnson‘s JNJ Tecvayli in combination with Darzalex ...

Commonly prescribed heart medications, including statins and diuretics, do not negatively affect the survival of ...

After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson & Johnson and Legend Biotech’s Carvykti has once again mounted a major ...

Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy1 ...

The phase 3 SUCCESSOR-2 trial shows mezigdomide-based therapy improves PFS in R/R multiple myeloma patients previously exposed to lenalidomide.

The American Cancer Society’s Cancer Statistics, 2026 report highlights a historic milestone: the 5-year relative survival rate for all cancers combined has reached 70%, up from 49% in the mid-1970s.

In second- or later-line setting, combination cut risk of disease progression or death by ...

Johnson & Johnson’s standout trial results for its Tecvayli and Darzalex Faspro pairing in previously treated relapsed or ...

Rapid Novor Inc., a Canadian biotechnology leader, announced today that its diagnostic laboratory has received a provisional license from the Ontario Ministry of Health (MOH) for its EasyM® assay, ...

Mezigdomide (a CELMoD) combined with carfilzomib/dexamethasone met the phase 3 primary endpoint, delivering statistically ...